Yodfat Harel Buchris
More info
Yodfat is a managing director at Blumberg Capital, based in Tel Aviv. Yodfat is an experienced investor and board member with a track record in management, business development, marketing and strategic planning in North America, Europe and Asia.
Prior to joining Blumberg Capital, Yodfat ran her own investing and consulting business. Previously, she was managing director of Tamares Capital Ltd, a large international private investment fund with holdings in technology, media, manufacturing and real estate. Earlier, Yodfat served as corporate director and head of the medical and venture capital groups at Orbotech LTD, a world leader in automated inspection for printed circuit boards and panel displays.
She also previously served as managing director at Harel-Hertz Investment House Ltd. managing investment and business development for Japanese and Israeli corporations and as chief advisor to ITX-Corporation, a leading Japanese electronics conglomerate listed on NASDAQ Japan.
Yodfat serves on the board of directors of Israel Discount Bank and serves as an industry representative on the National Labor Court.
Yodfat earned her executive MBA from Bradford University School of Management in Great Britain and her B.A. in communications and political science from Bar-Ilan University. She has also completed advanced programs in director studies, mediation, advertising and marketing.
A groundbreaking antibody treatment for Alzheimer’s disease
A groundbreaking antibody treatment for Alzheimer’s disease developed by an Israeli scientist is currently headed toward a Phase I clinical trial. If successful, the treatment could become a game-changer for the disorder, modifying its course and preventing its progression.
Korea's Bio-Leaders To Invest $10 Million in Weizmann Institute Anti-Cancer Therapy
Bio-Leaders has agreed to commit $10 million towards a company being spun off of Yeda Research and Development, Weizmann’s technology transfer arm. Yongin, South Korea-headquartered biomedical company Bioleaders Corp. is looking at Israeli research institute The Weizmann Institute of Science for anti-cancer technology. BioLeaders has agreed to commit $10 million towards a company being spun off of Yeda Research and Development Co. Ltd., Weizmann’s technology transfer arm, the institute announced Tuesday.
Weizmann Institute’s new technology may help treat cancer
The Weizmann scientists used their technology to address issues that have challenged researchers for years: the failure of the immune system to recognize and kill cancer cells and the failure of immunotherapy in treating most classifications of tumors.The group’s next step is to develop immunotherapy treatment using specific antibodies for clinical use and Amit is currently working with Yeda Research and Development - the technology transfer arm of the Weizmann Institute - to do so.
Lysogene, Weizmann Institute Team Up on Gene Therapy for Neuronopathic Gaucher
Lysogene has entered into a collaborative research agreement with Yeda Research and Development, a commercial branch of the Weizmann Institute of Science, to develop a gene therapy for neuronopathic Gaucher disease that affects the brain and spinal cord, the biopharmaceutical company announced.
The therapy also will be investigated as a treatment for Parkinson’s disease and other disorders caused by mutations in the GBA gene.
Israeli natural food coloring co Phytolon raises $4.1m
Israeli natural food coloring developer Phytolon has announced that it has completed a $4.1 million financing round led by Millennium Food-Tech with the participation of Consensus Business Group (CBG) Fund, Trendlines Group, EIT-Food (the EU body responsible for food-tech initiatives), and former Elbit Systems CEO Yossi Ackerman. Phytolon's development is patent protected and belongs to Yeda, the technology transfer company of the Weizmann Institute of Science, which has granted Phytolon an exclusive license.
Potential Heart-Repair Protein Advances to a New Stage
Pre-clinical studies suggest a protein, Agrin, could limit scarring and promote natural repair mechanisms after a heart attack
“The road from basic research to the clinic is long and often bumpy, so our study in pigs provides a critical step in this direction,” Tzahor says. This study was made possible, in part, by a new program that aims to bridge the gap between promising basic science breakthroughs at the Institute and commercial application. Called IDEA (Innovation, Development, Enhancement and Acceleration), it is an initiative of Yeda, Weizmann’s technology transfer arm.
Personalized Nutrition - DayTwo
DayTwo is a start-up that provides personalized nutrition recommendations, which help balance individual blood sugar levels. In the following article, DayTwo Co-Founder and CEO Lihi Segal discusses the importance of health-tech and how the company copes with the current pandemic crisis. She also recalls meeting Weizmann Institute researchers Prof. Eran Segal and Prof. Eran Elinav – whose groundbreaking research serves as the company's IP backbone – and talks about how the successful collaboration between industry and academic research has generated a sustainable win-win scenario.
COVID-19 Supports Agrifood Startups
Phytolon has been selected by EIT Food to receive a share of €5.4 million in new funding.
The COVID-19 Bridge Fund supports #agrifood #startups at the forefront of European food innovation
Read more about the announcement here: https://lnkd.in/dbD9qjP
Phytolon (€393.6K, IL) uses an environmentally friendly fermentation-based technology to produce natural food colours that are GMO-free, high-quality and sustainable
A New Method for Seeing into Cells
Internal Differences: A New Method for Seeing into Cells
The new technology may help answer outstanding questions about the immune system, cancer, Alzheimer’s, and more.
Pages
